Dermatologic signs of biotin deficiency leading to the diagnosis of multiple carboxylase deficiencySEYMONS, Katia; DE MOOR, Anja; DE RAEVE, Hendrik et al.Pediatric dermatology. 2004, Vol 21, Num 3, pp 231-235, issn 0736-8046, 5 p.Article

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosisASOSINGH, Kewal; DE RAEVE, Hendrik; VAN RIET, Ivan et al.Blood. 2003, Vol 101, Num 8, pp 3136-3141, issn 0006-4971, 6 p.Article

Reproducibility of Histologic Classification in Nonfibrotic Myeloproliferative NeoplasiaKOOPMANS, Suzanne M; BOT, Freek J; LAM, King H et al.American journal of clinical pathology. 2011, Vol 136, Num 4, pp 618-624, issn 0002-9173, 7 p.Article

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneityASOSINGH, Kewal; DE RAEVE, Hendrik; MENU, Eline et al.Blood. 2004, Vol 103, Num 8, pp 3131-3137, issn 0006-4971, 7 p.Article

Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse modelVAN VALCKENBORGH, Els; CROUCHER, Peter I; VAN RIET, Ivan et al.The American journal of pathology. 2004, Vol 165, Num 3, pp 869-878, issn 0002-9440, 10 p.Article

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survivalCROUCHER, Peter I; DE RAEVE, Hendrik; PERRY, Mark J et al.Journal of bone and mineral research (Print). 2003, Vol 18, Num 3, pp 482-492, issn 0884-0431, 11 p.Article

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma modelNUR, Haneen; RAO, Luigia; MENU, Eline et al.British journal of haematology. 2014, Vol 167, Num 5, pp 651-663, issn 0007-1048, 13 p.Article

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of MyelomaDELEU, Sarah; LEMAIRE, Miguel; VANDERKERKEN, Karin et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 13, pp 5307-5311, issn 0008-5472, 5 p.Article

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP : an in vitro and in vivo study in the 5T33MM mouse modelMENU, Eline; JERNBERG-WIKLUND, Helena; VANDERKERKEN, Kann et al.Blood. 2006, Vol 107, Num 2, pp 655-660, issn 0006-4971, 6 p.Article

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera : Therapeutic implicationsMICHIELS, Jan J; BERNEMAN, Zwi; VAN BOCKSTAELE, Dirk et al.Seminars in thrombosis and hemostasis. 2006, Vol 32, Num 3, pp 174-207, issn 0094-6176, 34 p.Article

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse ModelKHARAZIHA, Pedram; DE RAEVE, Hendrik; ZHIVOTOVSKY, Boris et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 20, pp 5348-5362, issn 0008-5472, 15 p.Article

Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myelomaVANDERKERKEN, Karin; MEDICHERLA, Satya; CROUCHER, Peter I et al.Cancer research (Baltimore). 2007, Vol 67, Num 10, pp 4572-4577, issn 0008-5472, 6 p.Article

The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM modelMENU, Eline; ASOSINGH, Kewal; VANDERKERKEN, Karin et al.Haematologica (Roma). 2006, Vol 91, Num 5, pp 605-612, issn 0390-6078, 8 p.Article